Valion Bio Seeks New 1-for-2 to 1-for-12 Reverse Split and 272,000-Share Plan Increase
VBIO is trading near its 52-week low of $1.11 (3.6% above the low) on light trading volume (0.2× avg).
Summary
Valion Bio's definitive proxy asks shareholders to approve a new 1-for-2 to 1-for-12 reverse split and a 272,000-share increase to its equity incentive plan at a November 12 special meeting.
Key Events · Corporate Governance and Compliance · VBIO
-
New Reverse Split Authorization Proposed
Board seeks discretionary authority for a 1-for-2 to 1-for-12 reverse split within 12 months, separate from the 1-for-25 split executed August 31, 2026.
-
Equity Plan Increase to 400,783 Shares
Proposal adds 272,000 shares to the 2021 Plan, raising the total reserve to 400,783 shares, or roughly 12.6% of the 2,155,637 shares outstanding as of the record date.
-
Special Meeting Set for November 12, 2026
Virtual meeting with record date October 15, 2026; preferred shareholders are not entitled to vote on any proposal.
-
Nasdaq Listing Pressure Drives Split
The reverse split is intended to maintain the $1.00 minimum bid price required for continued Nasdaq Capital Market listing.
Analysis · VBIO · Life Sciences
Valion Bio is asking shareholders to approve a fresh reverse split authorization of 1-for-2 to 1-for-12, separate from the 1-for-25 split already executed on August 31, 2026. The company is also seeking 272,000 additional shares for its 2021 Equity Incentive Plan, raising the total reserve to 400,783 shares. With only 2,155,637 common shares outstanding and a stock price near its 52-week low, the reverse split is aimed at maintaining Nasdaq's $1.00 minimum bid price and avoiding delisting. The equity plan increase is a smaller but real dilution overhang, representing roughly 12.6% of current shares outstanding if fully issued.
How filings like this one have moved
In the 30 days to Oct 16, 2026, 29.5% of the 1476 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.41%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, VBIO was trading at $1.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3M. The 52-week trading range was $1.11 to $75.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.